Scaled Average Bioequivalence (SABE)

Authored by: Laszlo Endrenyi , Laszlo Tothfalusi

Encyclopedia of Biopharmaceutical Statistics

Print publication date:  August  2018
Online publication date:  August  2018

Print ISBN: 9781498733953
eBook ISBN: 9781351110273
Adobe ISBN:

10.1201/9781351110273-140000115

 Download Chapter

 

Abstract

The approach of scaled average bioequivalence (SABE) standardizes, by the within-subject standard deviation, the more frequently applied method of unscaled average bioequivalence. The US Food and Drug Administration recommends that SABE be applied for determining bioequivalence (BE) for drugs that have large within-subject variation and also for those that have a narrow therapeutic index. The European Medicines Agency suggests another procedure for the evaluation of BE of highly variable drug products. Average BE with expanding limits (ABEL) is closely related to SABE and has similar characteristics. Both SABE and ABEL require fewer subjects than unscaled average BE with highly variable drugs. The contribution discusses their background as well as their statistical and regulatory features and presents procedures for their implementation.

 Cite
Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.